The EGFR pathway activated by EREG and the PI3K/Akt/mTOR pathway activated by FGF10 are well known to be part of the mechanisms of resistance to HER2-targeted therapy in HER2-positive breast cancer [28,30,31]. Here, EREG is linked to breast carcinoma.